Caris Upgrades Par Pharmaceutical (PRX) to Above Average
More News related to PRX
- Par Pharmaceutical Announces Results of Its 'Modified Dutch Auction' Tender Offer
- Par Pharmaceutical to Host Analyst Day on December 3rd
- Par Pharma (PRX) Receives Final U.S. FDA Approval for Tramadol ER Doses
- Par Pharmaceutical Receives Final Approval to Market Generic Ultram(R) ER
- Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Curren
Caris & Co. upgrades Par Pharmaceutical (NYSE: PRX) from Average to Above Average.
Par Pharmaceutical Companies, Inc., through its subsidiary, Par Pharmaceutical, Inc. develops, manufactures, and distributes generic and branded pharmaceuticals drugs in the United States.
Related Categories
UpgradesStocks Mentioned
+0.72Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
